These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9850638)

  • 1. Improved detection of adenocarcinoma of serous fluids with p53 immunocytochemistry.
    Saleh HA; Bober P; Tabaczka P
    Acta Cytol; 1998; 42(6):1330-5. PubMed ID: 9850638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
    Hafez NH; Tahoun NS
    J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids. Comparison with the diagnostic accuracy on small histologic biopsies.
    Spieler P; Gloor F
    Acta Cytol; 1985; 29(5):753-67. PubMed ID: 2996273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 immunostaining as a marker of malignancy in cytologic preparations of body fluids.
    Tiniakos DG; Healicon RM; Hair T; Wadehra V; Horne CH; Angus B
    Acta Cytol; 1995; 39(2):171-6. PubMed ID: 7887063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Ki67 immunostain in identification of malignancy in serous effusions.
    Saleh H; Bober P; Tabaczka P
    Diagn Cytopathol; 1999 Jan; 20(1):24-8. PubMed ID: 9884823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin.
    Athanassiadou P; Athanassiades P; Lazaris D; Kyrkou K; Petrakakou E; Aravantinos D
    Acta Cytol; 1994; 38(5):718-22. PubMed ID: 8091904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions.
    Mensch LS; Weller L; Simmons-Arnold L; Gibson PC; Leiman G; Beatty B
    Acta Cytol; 2002; 46(5):813-8. PubMed ID: 12365212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
    Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
    Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of p53 protein in the study of serous effusions.
    Zoppi JA; Pellicer EM; Sundblad AS
    Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squamous cell carcinoma in serous effusions: Avoiding pitfalls in this rare encounter.
    LePhong C; Hubbard EW; Van Meter S; Nodit L
    Diagn Cytopathol; 2017 Dec; 45(12):1095-1099. PubMed ID: 29024544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells.
    Walts AE; Said JW; Koeffler HP
    Mod Pathol; 1994 May; 7(4):462-8. PubMed ID: 8066074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
    Afify AM; al-Khafaji BM
    Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-strand conformational polymorphism (SSCP)-detected p53 gene mutations are a less sensitive marker of malignancy in pleural fluids than p53 immunostaining.
    Mayall F; Cursons R; Jacobson G; Chang B
    Cytopathology; 1999 Aug; 10(4):259-62. PubMed ID: 10458502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchioloalveolar carcinoma: diagnostic pitfalls and immunocytochemical contribution.
    Saleh HA; Haapaniemi J; Khatib G; Sakr W
    Diagn Cytopathol; 1998 Apr; 18(4):301-6. PubMed ID: 9557268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic value of p53 protein examination in lung cancer through preoperative fibro-optic bronchoscope brushing and biospy].
    Yu Q; Xiao Z; Liu G
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):445-7. PubMed ID: 10920941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
    Zhu W; Michael CW
    Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry.
    Queiroz C; Barral-Netto M; Bacchi CE
    Acta Cytol; 2001; 45(1):18-22. PubMed ID: 11213499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.